Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT116
- Development stage
- Phase 2
- Lead developer
- BioNTech
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
BNT116 is an intravenously administered mRNA-based therapeutic cancer vaccine developed for the treatment of non-small cell lung cancer (NSCLC). It consists of six RNA molecules, each encoding a tumor-associated antigen (TAA) frequently expressed in NSCLC. Delivered as an RNA-lipoplex formulation, BNT116 is designed to educate cytotoxic T cells to recognize and eradicate malignant cells by presenting these TAAs to the immune system. The drug leverages BioNTech's FixVac platform and aims to induce strong T cell responses against shared tumor antigens in NSCLC. Clinical trials are evaluating its safety and efficacy both as monotherapy and in combination with other agents such as cemiplimab (a PD-1 inhibitor), docetaxel, carboplatin/paclitaxel, anti-CTLA-4 antibody (BNT316), anti-B7-H3 ADCs, or anti-HER3 ADCs[1][3][5][7][8].
- Brand names
- FixVac Lung
- Other names
- FixVac Lung Cancer Vaccine
02
Targets
CLDN6 (Claudin-6)CT83 (Kita-Kyushu lung cancer antigen 1)MAGEA3 (Melanoma-associated antigen 3)MAGEA4 (Melanoma-associated antigen A4)MAGEC1 (Melanoma antigen family C1)PRAME (Preferentially expressed antigen in melanoma)
Beyond the preview
Go deeper on BNT116.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT116.